지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2012.1
- 수록면
- 127 - 132 (6page)
이용수
초록· 키워드
오류제보하기
Purpose The purpose of this study was to determine the efficacy and safety of treatment using gemcitabine and capecitabine for patients with advanced pancreatic cancer.
Materials and Methods Patients with advanced unresectable pancreatic adenocarcinoma were enrolled in the study.
Inclusion criteria included no prior systemic chemotherapy or radiation therapy, at least one radiographically documented and measurable tumor lesion, and adequate patient organ functions.
The patients received 1,000 mg/m2 gemcitabine intravenously on days 1, 8 and 15, and 830 mg/m2of oral capecitabine twice a day on days 1-21 of a 28-day cycle.
Results Fifty patients with a median age of 53 years (range, 39 to 76 years) were enrolled in the study. The median follow-up was 10.0 months. The objective response rate of the 50 patients was 48.0% (95%CI, 22.5 to 57.1%). The median time to progression and overall survival were 6.5 months (95% CI,2.3 to 8.7 months) and 10.0 months (95% CI, 5.7 to 16.7 months), respectively. Grade 3-4 toxicities associated with chemotherapy included neutropenia (22%), anemia (8%), thrombocytopenia (6%),and hand-foot syndrome (10%).
Conclusion Combination chemotherapy using gemcitabine and capecitabine was well tolerated and demonstrated promising efficacy in the treatment of advanced pancreatic cancer.
목차
등록된 정보가 없습니다.
참고문헌 (24)
참고문헌 신청
Herrmann R / 2007 / Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer : a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group / J Clin Oncol 25:2212~2217
Harsha HC / 2008 / Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy / J Proteome Res 7:4651~4658
Moore MJ / 2007 / Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group / J Clin Oncol 25:1960~1966
Philip PA / 2009 / Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment / J Clin Oncol 27:5660~5669
Abou-Alfa GK / 2006 / Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer / J Clin Oncol 24 : 4441
Harsha HC / 2008 / Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy / J Proteome Res 7:4651~4658
Moore MJ / 2007 / Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group / J Clin Oncol 25:1960~1966
Philip PA / 2009 / Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment / J Clin Oncol 27:5660~5669
Abou-Alfa GK / 2006 / Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer / J Clin Oncol 24 : 4441
이 논문의 저자 정보
최근 본 자료
댓글(0)
0